Tag Archives: Biotechnology

Neurosoft Bioelectronics Receives Nearly $3 Million in Funding

NEW YORK, N.Y. /ScoopCloud/ -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant. Additionally, the firm secured a $100,000 convertible note from the Fongit Innovation Fund.

Proceeds will fund continued development of the company's soft flexible electrodes to be marketed as SOFT ECoG™, a family of implantable devices which can seamlessly interface with the brain. The novel devices are up to 1000x softer and 2x thinner than clinical electrodes, with integrated electrode sites up to 100x smaller, making them suited for high-resolution recording and stimulation of the brain for up to thirty days. Their conformability and softness make them ideally suited for placement in the sulci of the brain - hard to reach areas of the brain where many disorders may best be treated. The deep folds of a sulcus are inaccessible for other electrodes while SOFT ECoG can be safely and precisely placed for stimulation and recording.

"Given that 70% of the surface of the brain is buried in sulci, it was critical to develop a technology that could safely and effectively work in those spaces," said Neurosoft Bioelectronics' CEO, Nicolas Vachicouras, Ph.D. "We're eager to put these significant funds toward clinical testing and regulatory approval of SOFT ECoG in the upcoming months, which will simultaneously drive progress of SOFT TINNIT. Together, these products have the potential to bring relief to epilepsy, brain tumor, and tinnitus patients, and in the future will impact those living with other neurological disorders such as deafness, blindness, tetraplegia, and chronic pain."

Vachicouras will present an update about the company and technology at the Bioelectronic Medicine Forum in New York today.

Most of the funds are designated for the further development of SOFT ECoG however, the innovations made will simultaneously advance the company's second product, SOFT TINNIT™. SOFT TINNIT is a chronic implant to perform closed-loop neuromodulation of the cortex to provide relief for patients suffering from severe tinnitus. Severe tinnitus, which has no cure, affects more than 7 million people in the U.S. and Europe.

Learn more: https://www.neurosoft-bio.com/technology

About Neurosoft Bioelectronics

Neurosoft Bioelectronics Ltd. is a Swiss medtech spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL). Neurosoft Bioelectronics develops next generation soft implantable electrodes to interface with the brain for the treatment of severe neurological disorders. Its main product is a fully implantable closed-loop Brain-Computer Interface (BCI) to treat severe tinnitus, a condition that affects 7M people in the US and Europe, of which 7% attempt suicide every year. It is also developing a family of subdural electrodes intended for monitoring during brain tumor and epilepsy resection surgery.

Learn more at: https://www.neurosoft-bio.com/

RELATED LINKS:

https://neurotechreports.com/pages/bioelectronic-medicine-forum.html

Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.

Related link: https://www.neurosoft-bio.com/

Key Entrepreneurs to Present at 2022 Bioelectronic Medicine Forum

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.

Entrepreneur presenters at the conference include Attila Borbath, CEO of Synergia Medical, a European firm developing an optical vagus nerve stimulation system, Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, Jennifer Ernst, CEO of Tivic Health, Manfred Franke, CEO of Neuronoff Inc., and Anuj Bhardwaj, CEO of SecondWave Systems Inc.

Peter Staats, a bioelectronic medicine pioneer and co-founder and chief medical officer of electroCore Medical, will keynote the conference. Dr. Staats is internationally recognized for his work in developing and implementing minimally invasive procedures for a number of disorders, including COVID, and his patents have led to the use of novel pharmacologic agents. He is a past President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society.

Other speakers at the 2022 event include Marom Biksom, professor of biomedical engineering at City College of New York, Imran Eba, partner at Action Potential Venture Capital, Chihiro Hosoya, head of venture management and business development at Astellas Pharma, Eric Hudak, program director at the National Institutes of Health, and Hannah Claridge from TTP plc in the U.K.

Other sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties.

MST is the Platinum Sponsor of this year's event, while Valtronic is the Silver Sponsor.

Key topics will include promising new indications, alliances with bio/pharm firms, regulatory and reimbursement issues, and pricing/commercialization issues.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This fifth-annual conference will be a key meeting place for entrepreneurs and executives helping to found this industry."

For more information on the 2022 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

RELATED LINKS:
https://www.neurotechreports.com/

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.

Related link: http://www.neurotechreports.com/

Kalyagen Announces Supporting Partnership of Two South Florida PGA Events and PGA Associate Jerrel Gill

AUSTIN, Texas /ScoopCloud/ -- Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.

"I'm extremely excited to introduce Kalyagen to the South Florida PGA and the PGA Hope program benefiting veterans like myself and some of my team members," said Desmond Dogan, Director of Sales at Kalyagen®. "Being a former golf professional and club pro, I understand the grind that is associated with practicing, playing, teaching, running the pro shop and more. That's why I'm pleased that Kalyagen is sponsoring Jerrel Gill, presently a Class B-13 PGA Associate who played on the HBCU Hampton University golf team. Jerrel will be attempting to qualify to play in the South Florida Open."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

"Despite my local success, I am determined to improve my game and consistently compete against the best P.G.A. Professionals," said Jerrel Gil, PGA professional golfer. "I have been noticing a deficiency in strength and recovery compared to my competitors. As a result, I have been fortunate enough to partner with Kalyagen and use its stem cell enhancement supplement STEMREGEN to assist in my 2022 journey to contend in the South Florida PGA Section and hopefully on the PGA Tour!"

"We are delighted to partner with Jerrel and the South Florida PGA Section," said Kalyagen® founder and CEO Christian Drapeau. "The link between a lower number of circulating stem cells and the development of age-related diseases and lack of recovery has been well studied. From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair and improve the course of disease formation in many degenerative conditions and overall health and well-being that should benefit Jerrel's training and recovery efforts. We can't wait to see his journey in golf rollout this season with the benefits of STEMREGEN on his team."

About Kalyagen

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/.

About South Florida PGA

The South Florida Section of the PGA of America is an association of golf professionals whose mission is to promote interest, participation and enjoyment of the game of golf; establish and maintain professional standards or practice; and enhance the well-being of golf professionals. With over 460 facilities in the region employing over 1,850 members and Associates, the South Florida Section of the PGA is the second largest Section of PGA Professionals amongst all 41 PGA Sections in the U.S. The South Florida PGA Foundation has had the ability to reach more than 15,00 individuals since its inception, and PGA HOPE has impacted more than 860 veterans since 2015. For more information, please visit: https://www.sfpgagolf.com/.

About Jerrel Gill

Jerrel Gill has excelled in various management fields since graduating with honors from Hampton University with a Bachelor's of Science in Business Management. Hampton University is a historic Black college and university in Hampton, Virginia. Mr. Gill reentered the golf industry as a registered PGA Associate in April of 2019 and was quickly promoted to Assistant Golf Professional at Plantation Preserve Golf Course and Club in Plantation, Florida. In March 2020, he was promoted to General Manager of The Bridges at Springtree Golf Club in Sunrise, FL. During the last three years as a PGA Associate, Mr. Gill has quickly made himself known as a competitive golfer in the South Florida PGA Section. His best finish was a tie for 2nd place at the 2021 DEK Classic with an additional five top-15 finishes in the Southern Section in 2021.

About Desmond Dogan

Following high school and a once-in-a lifetime experience with the USA Jr. National Olympic Hockey Team, Mr. Dogan served as a Navy Corpsman. After a successful five-year stint with the Navy, Mr. Dogan spent the next twelve years as an Operating Room Technician at LA-based Cedar Sinai Medical Center. After graduating from the Orlando Chapter of the Golf Academy of America and passing the PGA playing ability test on his first attempt, Mr. Dogan was offered the Head Professional position at the famed Inverrary Country Club. This led to a Head Professional/ Director of Golf position with the Billy Casper Golf Management group in Chicago. In addition to his current role with Kalyagen®, Mr. Dogan continues to be heavily involved in the not-for-profit world.

MEDIA CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen @southfloridapga #kalyagen #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #pga #southfloridapga #jerrelgill

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.

Related link: https://www.kalyagen.com/

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

The research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.

"This collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification," Dr. Bestard stated.

"Today, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management," said Dr. Buchli.

Steve Mayer MD, Chief Medical Officer at PTS stated, "We're very excited about the potential of this technology because it allows a very early diagnostic view of an individual's risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its ecommerce website, https://www.hlaprotein.com/, Pure Protein offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Vall d'Hebron Barcelona Hospital Campus

We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management. The Vall d'Hebron Barcelona Hospital Campus is the combination of our five entities: the Vall d'Hebron University Hospital, the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron Oncology Institute (VHIO), the Multiple Sclerosis Center of Catalonia (CEMCAT) and the Autonomous University of Barcelona.

We are constantly in touch with patients; our starting point is the challenges they present in our day-to-day work to continue to innovate and find new diagnostic methods and treatments. The talented team that has made us a leading institution allows us to work towards attracting excellence and training the best professionals in clinical practice.

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

Related link: https://www.puretransplant.com/

Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D., that measures antibody-secreting B cells. Oxford Immunotec exclusively licensed the patented technology in 2015 from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, where Dr. Bestard performed his research.

"We are thrilled to add this assay to our portfolio of diagnostic solutions," said Blake Harlan, President of Pure Transplant Solutions. "This assay, when combined with our proprietary HLA tetramer technology, offers a powerful new diagnostic tool for transplant physicians that we expect will improve patient care and extend graft life."

"We are excited about the potential for Pure Transplant Solutions to apply our B-Cell assay technology to new diagnostic solutions in transplant medicine," commented Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec.

The enabling results of the B cell measuring technology were originally published in The Kidney International in a study co-authored by Dr. Bestard and showed the efficacy of the B cell technology in identifying patients at high risk for rejection that were not identified by other serological tests. The 70-patient study included patients on a waiting list for kidney transplantation as well as kidney transplant recipients undergoing antibody-mediated rejection.

Independently, PTS has continued to expand its portfolio of soluble HLA reagents including monomers and tetramers. Today, PTS has one of the largest selections of Class I and Class II proteins which are offered to researchers for Research Use Only through the company's website http://www.hlaprotein.com/.

When used with original assay technology, the combined assay offers a powerful and enhanced diagnostic tool that is complementary to existing assays such as the Panel of Reactive Antibodies (PRA) test and the Donor Specific Antibody (DSA) test, which represent the standard of care for the assessment of the likelihood of an antibody-driven rejection event in transplant patients. The PRA and DSA tests depend on the identification of antibody levels to foreign Human Leucocyte Antigens (HLA) in the blood. Because these levels fluctuate or the antibodies disappear entirely for various reasons, patients at-risk for rejection are often missed.

The enhanced B cell addresses this problem by directly measuring the underlying B cells themselves, which have the potential to rapidly react to a donor organ and produce antibodies that contribute to acute rejection. By measuring these specific foreign HLA antibody-secreting B cells, the test is able to identify such sensitized patients regardless of the presence of circulating antibodies, potentially identifying at-risk patients missed by the PRA and DSA tests.

NOTES:

[1]Lúcia M et al. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney International advance online publication, July 15, 2015; doi:10.1038/ki.2015.205

Definitions

HLA - Human Leucocyte Antigens - Proteins on the surface of cells that are responsible for regulation of the immune system and particularly responsible for the ability of the immune system to recognize self from non-self.

PRA Test - Panel of Reactive Antibody test - An immunological laboratory blood test that assesses the extent to which the patient on the transplant waiting list will react, via pre-existing antibodies, to non-self. Any PRA score indicates that the patient has a higher risk of antibody mediated graft rejection.

DSA Test - Donor Specific Antibody test - An immunological laboratory blood test that assesses the presence of antibodies in the transplant patient that are generated specifically against the donor's HLA type. The presence of DSA indicates that the patient has a higher risk of antibody-mediated allograft rejection. Pre-transplant, the DSA test indicates which donor HLA types may not be tolerated or would carry a higher risk of antibody-mediated graft rejection. Post-transplant, persistence or appearance of DSA may indicate a high risk of ongoing or future antibody mediated graft rejection.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Learn more: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Oxford Immunotec, Ltd.

Oxford Immunotec is a global diagnostics company and part of PerkinElmer Inc. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease. Oxford Immunotec is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection.

The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States (where it has received pre-market approval from the Food and Drug Administration), Europe (where it has obtained a CE mark), as well as Japan and China. The recently released T-SPOT.COVID test is CE marked in Europe for clinical use to detect the T cell immune response to SARS-CoV-2 (www.tspotcovid.com). Oxford Immunotec is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at https://www.perkinelmer.com/.

Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.

Related link: https://www.puretransplant.com/

Neurotech Reports Announces Launch of New Publication Serving Bioelectronic Medicine Industry

SAN FRANCISCO, Calif. /ScoopCloud/ -- Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine, which refers to the therapeutic use of electrical or other forms of stimulation, rather than drugs, to treat disorders.

The publication was introduced at the Neurotech Leaders Forum, which takes place November 8-9, 2021 in San Francisco.

James Cavuoto, editor and publisher at Neurotech Reports, said that bioelectronic medicine promises to alter fundamentally the nature of therapeutic interventions for treating a wide variety of conditions, ranging from inflammatory disorders to bowel and bladder disorders, and a host of other potential markets in which drug therapies have fallen short. "We plan to be the most up-to-date and authoritative source of information and analysis of the market, the major players, deal activity, and important clinical research in bioelectronic medicine," he said.

Cavuoto is the lead author of Neurotech Report's market research study, "The Market for Bioelectronic Medicine: 2022-2027." Neurotech Reports launched the Bioelectronic Medicine Forum in New York City in 2018, and plans to return to New York for the fifth annual event in April 2022.

Helping launch the new publication is consulting editor Susan Schaeffer, former editor of BioCentury, the leading industry newsletter for the pharmaceutical industry. In that role, she advanced new thinking in clinical trial development, regulation, pricing, and market access-factors that will be critical in bioelectronic medicine. She is also a member of the National Academies Forum on Drug Discovery, Development, and Translation and founder of a patient education nonprofit.

"Bioelectronic medicine is rapidly bringing a new modality forward for targeted and personalized medicine-a space that has been dominated by biopharmaceutical companies," said Schaeffer. "BioElectRx Business Report will have a particular focus on the potential for collaboration between these historically separate sectors, and will shed light on the potential of this new technology to treat serious diseases, either without, or in conjunction with drugs."

Contributing editor Jo Jo Platt, who has worked with many bioelectronic medicine pioneers during her career, will round out the editorial team for BioElectRx Business Report.

For more information on subscribing to BioElectRx Business Report, contact Neurotech Reports at 1-415-546-1259, or visit: https://www.neurotechreports.com/pages/BioElectRx-newsletter.html

For more information on Neurotech Reports, visit: https://neurotechreports.com/

Learn more about the Neurotech Leaders Forum at: https://neurotechreports.com/pages/leadersforum.html

Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.

Related link: http://www.neurotechreports.com/

Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium

AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

Mr. Drapeau also visited Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy regarding the ongoing multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Dr. Garber will be the primary contact in Europe for STEMREGEN®.

"We are delighted that we will now be able to offer STEMREGEN to the people of Spain. The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the spring of 2022, aims to evaluate the effect of ESCM in cases of heart failure. Study participants will be evaluated over several months, at which times their NYHA functional classification and echocardiographic parameters will be assessed.

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our website: https://www.kalyagen.com/.

About Miguel Garber

Miguel Garber over 32 years experience in Internal medicine and cardiology, with expertise in regenerative medicine, training and education, research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Española de Medicina Regenerativa y Terapia Celular. Dr. Garber can be reached at mggarber@gmail.com.

CONTACT:

Biomics, LLC (dba Kalyagen™)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

Related link: https://www.kalyagen.com/

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus. Their CAR is directed against CD19 and BCMA surface proteins generating a cCAR with dual expression of CD19 and BCMA CAR molecules. Their cCAR is one of a kind in the family of engineered CAR T-cells researchers are studying.

Their report "Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR" published on August 30, 2021, shows the clinical success of cCAR in treating a patient with Systemic Lupus Erythematosus (SLE).

According to Dr. Yupo Ma, founder of iCell Gene Therapeutics, "After a single infusion of CD19-BCMA cCAR the patient achieved undetectable levels of autoantibodies that mediate SLE, successfully treating the patient's SLE for 2 years without the need for additional medications."

The publication is available online at https://doi.org/10.1007/s12015-021-10251-6.

About SLE

Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease, in which autoantibodies attack its own tissues, resulting in widespread tissue damage in the affected organs including kidneys, lungs, joints, brain and blood vessels. According to the Lupus Foundation of America, it estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.

About CD19-BCMA cCAR Therapy

iCell has developed a novel compound Chimeric Antigen Receptor (cCAR)approach. In this approach, the cCAR T cells express two distinct and fully functional CAR molecules, one that targets the molecule CD19 present on B cells and one that targets BCMA, which is present on plasma cells. In their recently published paper, researchers have shown that this cCAR led to rapid and dramatic decreases in B cell levels and levels of "autoantibodies" (antibodies that attack the body's own cells) in a patient with SLE.

As B cells are part of the normal immune system, it is preferable that the elimination of B cells be temporary. After 9 months of B cell depletion, the patient's B cells returned to normal. Importantly, the levels of autoantibodies remained undetectable. Based on these results, the researchers concluded that cCAR effectively "reset" the antibody-producing populations. In this "reset," the problematic cell populations were removed, leaving behind a fresh, clean slate. From this, new B cells and plasma cells were eventually formed, which did not have the same autoantibody-producing properties. Because of this, the patient has not had further lupus symptoms despite receiving no additional medications for over 2 years.

Given the prevalence of antibody-mediated disorders, this cCAR may prove useful for a variety of different medical conditions.

Sjögren's Syndrome, autoimmune hemolytic anemia, neuromyelitis optica spectrum disorder, celiac disease, type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, psoriasis, and multiple sclerosis all incorporate autoantibody formation in disease pathogenesis. Additionally, organ rejection following transplantation may be mediated by antibodies. By "resetting" the immune system prior to organ transplantation, this antibody-mediated rejection may be avoided. More research is needed on the long-term efficacy and safety of this treatment, but future applications of cCAR has a large window of opportunity.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Their main focuses are on autoimmune disorders, AML, and T-cell malignancies. Their current clinical trials utilize their CARvac, T-cell targeted CARs, cCARs and non-gene edited universal CARs engineered as treatments for cancer, organ rejections and autoimmune diseases. These studies are ongoing in the US and China for their use.

For more information, please visit http://icellgene.com/

CONTACT:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

RELATED LINKS:

https://www.lupus.org/resources/how-many-people-have-lupus-in-the-united-states

https://www.lupus.org/resources/what-is-lupus

iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Related link: http://icellgene.com/

Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors

ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.

During Harry's 25 years of service as Mayo's Chief Investment Officer and Treasurer which ended December 2020, Mayo Clinic achieved top decile investment performance among a universe of major tax-exempt institutions and grew its investment assets by over ten-fold. Outside of Mayo, Harry has served on the boards of several large family offices and is a former trustee of the Endowment Board of the American Red Cross, The Investment Fund for Foundations (TIFF) and The Ronald McDonald House of Rochester. He is also a founding member and vice chair of the Southeast Minnesota Capital Fund.

"I am delighted to welcome Harry onto the Vyriad Board. He has a deep understanding of Vyriad and its history, and I am very much looking forward to working with him as we take this exciting Company to its next level," said Ed Kania, Vyriad's Chairman of the Board.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence. Our lead platforms, derived from either vesicular stomatitis virus (VSV) or measles virus, are being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types.

Vyriad and Regeneron (NASDAQ: REGN) are engaged in a broad strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo(r) (cemiplimab) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit hhttps://vyriad.com/.

CONTACTS:

Investor Relations:

Barb Duckett

bduckett@vyriad.com

(507) 289-0944

Media Relations:

mediarelations@vyriad.com

yriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.

Related link: https://vyriad.com/

KROST Acts as Exclusive Financial Advisor for Integrity Bio in Sale to Curia

LOS ANGELES, Calif. /ScoopCloud/ -- Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.

Integrity Bio is known in the biopharmaceutical industry as an expert in hard-to-formulate biologics and fill-finish of unique therapies for phase I and phase II clinical trials. Integrity Bio formulates more than 60 large molecules in a typical year, including proteins, antibodies, lipid nanoparticles, peptides, and vaccines in liquid and lyophilized form. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three facilities. The acquisition adds West Coast operations to Curia's East Coast and overseas capabilities.

Integrity Bio has been a client of KROST for ten years, during which time KROST provided Tax, Accounting, Consulting, R&D Tax Credit, Cost Segregation, and now, Mergers and Acquisitions services. KROST's service model is designed to guide and support businesses throughout their lifecycle, from early-stage start-ups to succession and exit planning.

KROST's M&A practice is led by industry veteran, Paren Knadjian, who joined the firm in 2017. Knadjian has nearly 25 years of experience in mergers and acquisitions, equity and debt financing. He has closed over $1.5 billion in transaction value throughout his career. As the leader of the firm's technology industry niche, Paren also assists companies in the business of technology and life sciences innovation.

"We have been advising Integrity Bio, its owners and management team for over 10 years. So when they were considering a sale, they turned to us to help them with deal value, deal structure, due diligence, accounting and tax matters, and transactional support. This acquisition comes at a meaningful time for the country. The work that Integrity Bio is doing, and will continue to do as part of Curia, will contribute to life-changing cures for health issues, much like we experienced in the last year and a half. This acquisition is not just a transaction; it has a huge impact on people's lives across the globe. I am thrilled we were able to assist Integrity Bio with this transition into their next chapter and look forward to seeing what Curia will do with their added capabilities," remarked Paren Knadjian.

"We would like to thank the KROST team - they were invaluable in this transaction, and we relied on them enormously," said Michael Reilly, CEO of Integrity Bio. "As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing."

For more information about KROST's mergers and acquisitions, as well as capital markets services, visit https://krostcpas.com/ or contact Paren Knadjian.

For information about this transaction, please contact:

Paren Knadjian

Practice Leader - M&A and Capital Markets

626.538.3167

paren.knadjian@krostcpas.com

ABOUT KROST CPAS & CONSULTANTS

KROST is a full-service Certified Public Accounting and Consulting firm headquartered in Pasadena, California. As trusted advisors and industry leaders, clients depend on KROST for timely information, innovative solutions, and results-driven teamwork in the areas of accounting, assurance, business management, consulting, tax, mergers and acquisitions, and wealth management.

Twitter: @KROSTCPAs

Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.

Related link: https://www.krostcpas.com/

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital.

Related link: https://www.puretransplant.com/

BioAustin Appoints New Leadership and Unveils An Expanded Strategic Focus In Central Texas As BioAustinCTX

AUSTIN, Texas /ScoopCloud/ -- Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S. With more than 240 companies and a variety of nonprofit community ecosystem organizations involved in the life science sector, the Central Texas Region has emerged as a significant life science innovation center and is attracting investment for early-stage startups and relocations for established companies.

BioAustinCTX℠ is undertaking new initiatives to identify and facilitate programs to support the continued growth of the life science industry in the Central Texas region. This evolving strategy will encompass new programs to build collaboration, communication, and growth across companies, community partners, and academic institutions focused on the life science sector. Steps taken in the first six months include changes in Board leadership, repositioning the organization as BioAustinCTX with a broader focus across the Central Texas region, restructuring internal operations to improve efficiency, and the launch of a redesigned monthly newsletter and new website (https://www.bioaustinctx.com). Over the next year, BioAustinCTX will be rolling out new programs including the relaunch of its vaunted "BioBash" life sciences networking event.

John Burns Ph.D. and Mary Costello have stepped down from the BioAustin Board as of the end of 2020. Their time, commitment, and contributions over the past several years are greatly appreciated. Elisa Maldonado-Holmertz has served on the BioAustin Board of Directors since 2017 and will continue to serve on the BioAustinCTX Board. Elisa also serves on the Board of Directors of the Texas Medical Device Alliance.

Scott Collins PhD, CEO of Austin Innovation Group, was appointed as President of BioAustinCTX. Scott stated, "I will lead the organization with the expertise and guidance of the Board of Directors and through collaborations with our community partners, including THBI, TEXGHS, ACC, UT-Dell Medical School, Austin Chamber of Commerce, Austin Health Council, THBD, Texas Health CoLab, ACC Bioscience Incubator, Texas State Star Park, the Austin Technology Incubator and our members."

Newly appointed to BioAustinCTX Board of Directors as of January 2021 is Timothy Sullivan. Timothy is CEO of Zeteo Biomedical LLC, a Pflugerville, TX-based medical device company. Timothy has a long history of supporting the development of the life science industry in Central Texas over the past two decades. Timothy currently serves as an Advisor to the UT Dell Medical School Catalyst program, the ACC Bioscience Incubator, and is a founding member of the TEXGHS Global Health Security Consortium. Further expansion of the BioAustinCTX board is likely in the coming year.

Additionally, Cathy Diehl and Melissa Hartman joined the BioAustinCTX operations staff. Cathy took the lead position managing the new BioAustinCTX website and monthly newsletter production, and Melissa manages the back office accounting and bookkeeping tasks.

About BioAustinCTX

BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region. Visit BioAustinCTX for more information https://bioaustinctx.com, email: operations@bioaustinctx.com

Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.

Related link: https://bioaustinctx.com/

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas /ScoopCloud/ -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Pure MHC Solutions will provide collaborators access to Pure MHC's unique tools, experience, intellectual property, and infrastructure in HLA peptide target discovery, presentation, validation, and related competencies in a discrete, project-based manner. Pure MHC's core technologies are broadly applicable for oncology, autoimmune, and infectious disease indications.

Using its proprietary suite of intellectual property and related tools, Pure MHC Solutions works with partners seeking to elucidate how drugs and immune therapies alter, block, or enhance HLA antigen presentation to T-cells. This information can be used to determine a drug's potential efficacy, its mechanism of action, or to assist in defining the potency and tuning strategies for novel therapeutics.

Additional services and tools offered by Pure MHC Solutions also include its Peptide HLA Immunotherapy Data Resource ("PHIDR"), which is a proprietary healthy tissue database and repository used to guide TCR-based immune therapies to disease-specific targets by eliminating HLA/peptide complexes found on healthy tissues.

Pure MHC Solutions' project with argenx will support a more robust understanding of how antigen presentation changes in the presence of specific therapeutic agents, enabling more dynamic decision-making for its therapeutic programs.

"We are excited to offer our unique set of tools and services to collaborators such as argenx to assist with their autoimmune therapy programs," said Pure MHC President Kris Looney, "Pure MHC Solutions is uniquely positioned to provide access to these tools and has the deep HLA expertise that we believe will help drive better outcomes not only for our partners, but ultimately, for their patients."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Related link: https://puremhc.com/

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC), a developer of innovative immunoassays and the SirYus™ diagnostic platform technology, to develop personalized HLA diagnostics that will detect and quantify donor specific antibodies (DSA's) in post-transplant settings and provide the basis for post-transplant monitoring and early detections of transplant rejection.

The research is being led by Innobiochips co-founders Drs. Vianney Souplet and Christophe Olivier, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration aims to develop and validate new individualized, allele specific HLA-antibody diagnostics. The initial goals of the collaboration are to quickly develop the first commercial prototype and gather the data needed to validate the platform with leading community experts. The companies are optimistic that they will be able to rapidly provide a new portfolio of allele specific diagnostics to HLA lab directors, transplant clinicians and transplant patients that do not currently exist. These new diagnostics would enable personalized, easy to use, and quantifiable sequential monitoring of patient specific DSA levels, the result of which would provide a new pro-active window for clinicians to implement earlier graft saving interventions for transplant recipients.

"Between our two companies, we feel that we already have the ingredients needed to provide a new set of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins solve a number of important challenges on the serological side while the Innobiochips SirYus platform provides a very easy to use and elegant way to manufacture discrete, allele specific tests with the necessary controls, it really is a powerful combination."

"Over the past years, our companies have been exploring ways to combine our complementary technologies to create breakthrough diagnostics in the transplant market. PTS has the in-depth knowledge in HLA proteins and IBC has demonstrated that its technology is incredibly flexible and can enable as many as 144 serological assays at the same time in a single well, providing the transplantation departments an outstanding and new solution for HLA detection," Dr Souplet stated.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

Learn more: https://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Innobiochips

Innobiochips is a diagnostic company committed to provide innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and immunodeficiency and is partnering with several major players to incorporate the SirYus technology into larger IVD applications.

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC).

Related link: https://www.puretransplant.com/

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

Related link: https://www.puretransplant.com/

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas /ScoopCloud/ -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

The PHIDR healthy tissue database and repository will guide T Cell Receptor (TCR)-based immune therapy development to disease-specific targets by enabling developers to identify HLA/peptide complex targets found on healthy tissues. By screening potential target candidates against PHIDR, developers can confidently select, qualify, and focus efforts on those biomarker targets that minimize off-target or bystander effects.

The PHIDR database is representative of the full healthy human immunopeptidome as it includes HLA/peptide complexes expressed on multiple tissue samples from all over the body, with a focus on the vital organs. In addition to the peptide database, PHIDR includes a repository of matched cryopreserved tissue samples that enable complimentary orthogonal target validation techniques, including proteomics-based target quantification, genomics, and transcriptomics, on an as-needed basis.

For nearly 40 years, LifeNet Health has advanced medicine through the life-changing power of organ and tissue donation. Thanks to selfless donors, scientific discovery is advanced.

LifeNet Health LifeSciences has accelerated preclinical research and discovery through its growing portfolio of primary human cells and biospecimens for solutions that expedite research and allow the scientific community to develop and enhance new, safe therapies and medical breakthroughs.

"We are excited to offer access to the PHIDR database and repository to collaborators through our Pure MHC Solutions contract research arm," said Pure MHC President Kris Looney. "We could not have successfully built this resource without our collaborators at LifeNet Health. To be able to develop such a valuable resource for therapeutic development aligns nicely with LifeNet Health's mission to help patients live longer, healthier, and enjoy more active lives."

"We are proud to partner with Pure MHC and congratulate them on achieving success in their research efforts. Thanks to selfless donors, LifeNet Health is able to offer partners more than 40 types of biospecimens for research with over 200 protocols in place to meet the individual needs of researchers advancing scientific discovery," said Louis Dias, Vice President and General Manager of LifeNet Health LifeSciences. "The LifeNet Health LifeSciences team provides access to rare patient disease populations and enables researchers to unlock discoveries faster and with greater precision - offering the hope of new therapies to patients in need."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider - committed to advancing science, accelerating discovery, and optimizing outcomes. Leading the way in human in vitro biology, LifeSciences' game-changing innovations, currently under development, include models for the metabolic disease and oncology therapeutic areas and their related tools. For more information, go to www.LNHLifeSciences.org.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Related link: https://puremhc.com/

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

Related link: https://www.puretransplant.com/

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London, a leading university providing world-class teaching and cutting-edge research, to support the Phase IIa GAMECHANgER-1 clinical trial.

The trial aims to determine whether adoptive transfer of regulatory T cells (Tregs) into HLA sensitised patients can suppress memory T and B cell responses against specific HLA antigens in order to extend the longevity of donor organs.

The collaborative research is being led by Dr. Anthony Dorling, Professor of Transplant Inflammation and Repair, and Honorary Consultant Nephrologist at the Centre for Nephrology, Urology, and Transplantation, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration intends to investigate whether in vitro anti-HLA T & B cell responses in sensitized patients can be inhibited by an adoptive transfer of T regulatory cells. Under the Agreement, PTS will provide its proprietary soluble HLA (sHLA) molecules which will be used to trigger functional responses of patient cells in Fluorospot assays.

Furthermore, PTS will provide biotinylated sHLA for memory b-cell detection and characterization. Researchers hope that the results of the study will lead to a better understanding of immune tolerance, extend the duration of suppression of HLA-specific responses by Tregs and ultimately produce state-of-the-art immune therapeutics to control rejection.

"We feel that PTS has the fundamental ingredients needed to provide new sets of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins can solve a number of important challenges in DSA and B cell monitoring. With this collaboration, we are able to go beyond monitoring and help pave the way in generating immune therapeutics of the future."

"The group of highly sensitized dialysis patients that we'll be recruiting to GAMECHANgER-1 have difficulties getting a suitable kidney transplant and once transplanted suffer higher rates of rejection and complications associated with our current treatments for rejection," said Dr. Dorling. "This trial will determine whether patients' own regulatory T cells can be used to suppress immune memory responses against specific human leukocyte antigens (HLA), and if successful will pave the way for larger scale trials to determine if these regulatory cells can be used as therapy to prevent or minimise these problems in future. The HLA proteins provided by Pure Transplant Solutions are an essential tool used to tailor our immunemonitoring for individual patients, so I'm delighted to be partnering with the company to ensure a stable, long-term supply of these reagents. This trial offers a glimpse of how personalised medicine might help transform outcomes for this disadvantaged group of patients."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About King's College London

King's College London (King's) is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff. King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*).

Since its foundation, King's students and staff have dedicated themselves in the service of society. King's will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.

World-changing ideas. Life-changing impact: https://www.kcl.ac.uk/news/spotlight

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London.

Related link: https://www.puretransplant.com/

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

AUSTIN, Texas /ScoopCloud/ -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.

In addition to positive news received by the EPO, Heparinex is excited to announce that it has created a new class of sugar polymers, sulfated hepbiuronic acid (sHBA) that mimic some, but not all, of the desirable activities of heparin, a drug employed to treat many diseases including the fight against severe COVID-19 and influenza. These novel patent-pending drug candidates can quell the initiation of inflammation, but do not inhibit blood coagulation, thus can be used to protect organs such as the lungs, heart, and kidneys that are often damaged by the body's own defenses during disease without the risk of bleeding. The sHBA should be a useful addition to the arsenal of drugs currently dispensed to treat hyper-inflammation spawned by infectious, cardiovascular, and auto-immune diseases.

Heparosan conjugation was developed by Presidential Professor Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center (OUHSC) and includes a robust U.S. and international patent portfolio. "Our goal is to decipher and harness the natural 'sugar codes' in the body in more selective, customized fashion to target diseases and reduce side effects. We are excited by the possibilities for better medicines", said DeAngelis. He was named as one of the most influential researchers in the world according to a study led by an investigator at Stanford University and published in PLOS Biology.

About Caisson Biotech, LLC

Caisson Biotech, LLC is a collaboration driven biotechnology company specializing in the development of heparosan polymers to improve therapeutic drug delivery and performance. Caisson's HEPtune® technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist. Visit: https://caissonbiotech.com/.

Caisson Biotech is a subsidiary of Heparinex, LLC.

About Heparinex, LLC

Heparinex, LLC is a biopharmaceutical company focused on the novel recombinant synthesis of sugar-based compounds for markets including anticoagulation, inflammation, and cancer treatment. Dr. Paul DeAngelis originally discovered and patented Heparinex's core technology platforms of proprietary carbohydrate production. Visit: https://heparinex.com/.

Heparinex and Caisson are funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/

Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

Related link: https://caissonbiotech.com/

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif. /ScoopCloud/ -- Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

* Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic

* Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes

* Company seeks to expand team to support operational acceleration and development efforts

"Today, more than ever, we understand that pathogen-driven epidemics like Lyme disease need to be more easily and accurately diagnosed and more specifically treated with narrow-spectrum, targeted therapies to avoid the microbiome damage that occurs with broad-spectrum antibiotics," said Matt Tindall, Flightpath Co-founder and CEO.

Of the 476K patients diagnosed with acute Lyme disease each year in the U.S., most are treated with broad-spectrum antibiotics, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as Persistent Lyme disease (PLD). The etiology of PLD is not understood, and objective diagnostic tools are lacking.

Interestingly, PLD symptoms overlap several diseases in which patients exhibit alterations in their microbiome. In a recent study, published in mBio (September 2020), Lewis et al determined that microbiome sequencing data alone were indicative of late-stage Lyme disease, which presents a potential, novel diagnostic tool for PLD.

The authors found that patients with post-treatment Lyme disease syndrome, a subset of PLD, had a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. Importantly, this signature supports the validity of PLD and is the first potential biological diagnostic tool for the disease.

"Our ability to analyze the microbiome, transcriptome and metabolome and identify disease signatures will give us new tools to unlock the potential of microbiome-based medicines in rare infectious diseases and potentially pathogen-driven cancers," said Mark de Souza, Flightpath Co-founder and Executive Chairman. "We're excited to get to work with the Illumina team and our world-class lab and academic partners to tackle this disease area with fresh perspectives, novel approaches and new data."

About Flightpath Biosciences

Flightpath Biosciences is developing microbiome-targeted therapeutics and advanced biomarker-based diagnostics for the treatment of infectious diseases. Flightpath's mission is to transform patient's lives with medicines developed using a multidisciplinary approach to human and pathogen biology.

Please visit us at https://flightpath.bio/ and on Twitter at https://twitter.com/FlightpathB for more information.

Media Contact:
Michael Bellas
‪(510) 859-8668‬
https://flightpath.bio/contact-us/

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0209s2p-flightpath-300dpi.jpg

Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

Related link: https://flightpath.bio/

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services

AUSTIN, Texas /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

In his new role, Mr. Harlan will be responsible for leading Pure Protein's new product line commercialization while ensuring sustainable profitability and growth. He will also oversee the implementation and launch of Pure Transplant Solutions clinical diagnostics and transplant monitoring programs.

Going forward, Dr. Buchli will now be responsible for overseeing the products and services offered through HLAProtein.com in addition to expanding the portfolio of the companies' offerings. Furthermore, he will have the scientific oversight for the completion and launch of Pure Transplant Solutions' diagnostic products and monitoring programs.

"It's truly an exciting time for the Companies," said Mr. Harlan. "In the past twelve months we've built and launched our new website, established a robust pipeline of collaborations and developed new diagnostics for post-transplant monitoring. We've made the transformation from being a company solely developing technologies, to a company putting our products and tools in the hands of clinicians and researchers. We'll be launching a slate of new products and applications over the next several months and are all very excited for 2021."

"We wanted to build something more than just a website where you could place orders, we wanted to create a centralized resource for HLA research and education," said Dr. Buchli. "We've worked hard to incorporate the feedback from our collaborators and customers and are excited about the new products and services we'll be adding in the near future. In transplantation, we have ambitious goals and are optimistic about delivering solutions that improve patient outcomes."

Dr. Buchli earned his Ph.D. in Biochemistry from the University of Basel in 1996. He served as Postdoctoral Researcher at UC Davis under Drs. Sergei Grando and Dick Robbins and joined Pure Protein, LLC in March of 2001 as the Director of Research. Dr. Buchli has over 25 years of experience in molecular biology, biochemistry and immunology. As Director of Research, Dr. Buchli has developed multiple assay systems and has led the development of PTS's diagnostics portfolio.

Blake Harlan joined Emergent Technologies, Inc. (ETI) in January 2011, where his work and increasing responsibilities have focused on the commercialization of technologies spanning antimicrobials, plasma deposition, drug delivery, and immune oncology. He officially joined Pure Protein and PTS in 2016 and has been responsible for streamlining PTS's diagnostic development and commercialization strategies. He currently serves as Executive Vice President of Finance and Operations at ETI where he oversees the alignment and execution of all financial and operational objectives for ETI, its Funds and Portfolio Companies. Mr. Harlan holds a bachelor's degree in Economics from the University of Colorado at Boulder, and an MBA from the University of Texas at Austin.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies, products and services related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers the world's only and largest selection of soluble HLA (sHLA) proteins to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 2003 in order to leverage the HLA technology platform of its parent, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Today, PTS has developed a portfolio of diagnostic solutions to improve clinical outcomes related to antibody mediated rejection (AMR) and is working with collaborators to bring personalized transplant monitoring solutions to clinicians and their patients. Visit: http://www.puretransplant.com/

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0204s2p-harlan-and-buchli-300dpi.jpg

*Caption: Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services.

Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

Related link: https://www.hlaprotein.com/

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel, to develop new diagnostics for DSA monitoring and characterization in transplant rejection.

The research is being led by Prof. Stefan Schaub, Senior Physician at the Kidney Transplant Center, Gideon Hönger, Senior Researcher within the Transplantation Immunology & Nephrology Department, and Dr. Rico Buchli, Director of Research at PTS and its parent company, Pure Protein, LLC. The research project aims to develop and validate new HLA-antibody affinity/avidity assays.

The initial goal of the collaboration is to gather data that supports the correlation of the measured DSA binding properties with clinical outcomes in renal allograft recipients. If successful, such data will potentially enable a new diagnostic tool delivering a numerical risk factor rating indicating the prospective severity of rejection by classifying individual DSA from 'very harmful' to 'likely harmless.'

"These non-modified and naturally folded HLA monomers of Pure Proteins are ideally suited as reaction partners for patient HLA antibodies and for our intended kinetic measurements," Mr. Hönger stated. "Several research colleagues reported high satisfaction regarding the overall quality and functionality of sHLA from Pure Protein," said Prof. Schaub.

"Today, the immunological risk of an individual transplant patient is mainly assessed by the detection of HLA antibodies and their specificity in serum using single antigen bead assays. We envision that in addition to these tests, we can develop methods to measure the kinetics of donor-specific HLA- antibody interactions with our HLA proteins. If successful, this will provide new insight into HLA antibody pathogenicity that could help improve individual patient care and ultimately increase the lifespan of transplants," said Dr. Buchli.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. (www.etibio.com) that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: http://www.pureproteinllc.com/.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About University Hospital Basel

The University Hospital Basel is a tertiary hospital in northern Switzerland performing around 60-80 kidney transplantations per year. Further information can be found on the homepage of the hospital at https://www.unispital-basel.ch/en/ and on the clinic site at https://www.unispital-basel.ch/en/ueber-uns/bereiche/medizin/kliniken-institute-abteilungen/transplantation-immunology-nephrology/.

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0127s2p-pure-transplant-300dpi.jpg

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.

Related link: https://www.puretransplant.com/

Microcide Announces Launch of Speed-breaker for Fast Moving COVID-19 Infections for Health Care Facilities

STERLING HEIGHTS, Mich. /ScoopCloud/ -- Microcide® Inc. a leading Michigan based biotechnology company, today announced the test results of its COVID-19 faster virus killing range of products, PRO-SAN® Cleaner sanitizer, SILKY-SOFT® hand sanitizer, and DENTORAL® mouthwash.

Microcide®'s EPA registered PRO-SAN® L RTU sanitizer spray product has been found to kill 99.999% SARS-CoV-2 (COVID-19) within 30 to 120 seconds as tested by a prestigious national laboratory. PRO-SAN® L spray product offers quick and safe elimination of the virus without any harmful effects. PRO-SAN® can limit the speed of fast spreading COVID-19 infections.

COVID-19 vaccine protection is delayed by at least 10 days before immunity of the body kicks in. The use of current disinfecting chemicals containing chlorine, quaternary ammonium sprays, alcohol, and hydrogen peroxide alone or in combination offer disinfection protection which although effective, these products pose the possibility of indoor fire, and/or toxic pollution hazards. Additionally, these products cannot be freely used in enclosed spaces such as ho spital rooms. restaurants, school rooms, Day Care centers, planes, buses, and other public transportation systems where people are present.

PRO-SAN® L spray does not require such restrictions and can be conveniently used to control fast spreading COVID-19. Future COVID mutations should not affect the virus killing action of PRO-SAN® L.

Another unique feature of PRO-SAN® L spray is its long-lasting shelf stability and safety to handle, store, and transport. The product is freely available on our website as well as a limited number of retail markets as ready to use spray or instantly water-soluble powder concentrate.

More information: https://www.microcide.com/product-category/Pro-San

About Microcide:

Based in Sterling Heights, Michigan, Microcide® has been developing nontoxic antimicrobial products utilizing only FDA approved food grade and GRAS ingredients to provide safer cleaners and sanitizers for use both commercially and in the home. The USDA biopreferred PRO-SAN® product line is available as ready to use spray, powder concentrate, and liquid concentrates for use in cleaning food contact hard surfaces and washing fruits and vegetables. SILKY-SOFT® hand sanitizer can be used with or without water and is available as liquid or foam. DENTORAL® alcohol free mouthwash is available as powder concentrate in mint or clove or our children's bubble gum flavored sugar free SPRING-KISS®. Learn more: https://www.microcide.com/.

*(LOGO 72dpi: https://www.microcide.com/wp-content/uploads/2019/01/logo-e1579788873376.png )

*PHOTO link for media: https://www.Send2Press.com/300dpi/20-1229s2p-pro-san-family-300dpi.jpg

*Caption: Microcide® product family.

MEDIA ONLY CONTACT:
John A. Lopes Ph.D.
Of Microcide®, Inc.
+1-248-526-9663
lopes@microcide.com

Microcide® Inc. a leading Michigan based biotechnology company, today announced the test results of its COVID-19 faster virus killing range of products, PRO-SAN® Cleaner sanitizer, SILKY-SOFT® hand sanitizer, and DENTORAL® mouthwash.

Related link: https://www.microcide.com/

Synthetic Biology for Tennessee Schools: BioBuilder Partners with Niswonger Foundation on $8.8M Federal Grant for STEM Education

CAMBRIDGE, Mass. /ScoopCloud/ -- The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an "Education Innovation and Research" (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM).

BioBuilder will provide teacher professional development in the area of synthetic biology through their Essentials and Master Teacher workshops. BioBuilder's Professional Development workshops impact a teacher's understanding of biology and their approach to teaching it. Co-taught by a practicing synthetic biologist and a high school teacher, workshops combine classroom, laboratory, and design activities that are both accessible and inspiring. Participants leave with ready-to-teach lessons that bring engineering into biology classrooms, labs, and science clubs.

Aligned with both the Common Core and Next Generation Science Standards, the BioBuilder curriculum brings modern context to ideas and content traditionally taught in high school and college classes. At the high school level, BioBuilder has been used in General, Honors, and AP Biology as well as Biotechnology classes. In addition to teacher professional development, BioBuilder will support as many as 19 participating school districts with lab kits available through Carolina Biological Supply Company.

Students will participate in project-based learning through the BioBuilder Idea Accelerator, a program that teaches legitimate biotechnology skill building and data analysis through a team-based approach to creative problem solving and professional quality communication. Interested students may also elect to further pursue their biodesign projects with a dedicated mentor through BioBuilder's out-of-school-time activity, the BioBuilderClub.

This partnership builds on BioBuilder's work in recent years in the Kingsport City Schools, supported by the Eastman Foundation and Carolina Biological Supply Company. In January and July 2019, all the biology teachers at the Dobyns-Bennett High School, as well as teachers from other Kingsport schools and faculty from East Tennessee State University attended BioBuilder Professional Development workshops. Thanks to their training, teachers now plan to provide all 2,500 students at Dobyns-Bennett with hands-on training in synthetic biology over the next four years. After their pilot year, teachers have seen how their students respond to the BioBuilder labs in amazing ways.

Evie LaFollette, Secondary Science Teacher, Kingsport City Schools shared, "We've seen the full spectrum of students doing the BioBuilder labs, and they all enjoy it. They're asking, 'When do we get to do the next one?'"

The EIR grant was awarded to the Niswonger Foundation to fund the Rural Tennessee STEM.LD program. The concept of Learning Design (the "LD" in "STEM.LD") is defined as "the creative and deliberate act of devising new practices, plans of activity, resources and tools aimed at achieving particular educational results in a given context". BioBuilder joins the Niswonger Foundation in the belief that designing student-centered learning ecosystems and pathways can lead to positive student outcomes, from K-12 student achievement to meaningful employment in the workforce post-high school.

BioBuilder is one of a number of partners supporting the Rural Tennessee STEM.LD program. Other educational resources and partners will include cybersecurity experiential opportunities from the University of Alabama at Huntsville; expertise in curriculum design in engineering technology from Purdue University; East Tennessee State University's math, epidemiology, graphics design and computer science programs; the ETSU Research Corporation; and STEM project-based programs including STREAMWORKS, the Marine Advanced Technology in Education for Inspiration and Innovation; and "If I Had a Hammer."

Announcement from the U.S. Department of Education: https://www.ed.gov/news/press-releases/secretary-devos-announces-new-funding-accelerate-education-innovation-and-empower-teachers-professional-development-options-0

About the Niswonger Foundation

The Niswonger Foundation was established in 2001 to make a positive and sustainable difference in education in Northeast Tennessee. The Niswonger Foundation focuses on removing constraints to educational innovation and problem solving, thus allowing local school systems to better provide for student needs. By building school programs that are research-based and sustainable, the Niswonger Foundation has become a recognized voice for educational reform in the State of Tennessee, while nurturing the next generation of leaders. Learn more: https://www.niswongerfoundation.org/.

About BioBuilder Educational Foundation

Created by an award-winning team at MIT, BioBuilder offers new ways to teach, learn, and explore cutting-edge science and engineering. BioBuilder provides students the chance to integrate biology and engineering through practical, hands-on lessons, club activities, and school-to-work experiences. Teachers learn new methods of teaching that engage and inspire the young scientists in their classrooms.

Learn more: https://biobuilder.org/.

The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an "Education Innovation and Research" (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM).

Related link: https://biobuilder.org/

Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website https://www.hlaprotein.com/.

This new ecommerce website offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Rico Buchli, Ph.D., Pure Protein's Director of Research commented, "For over 20 years, Pure Protein has provided technology and expertise to advance novel therapies and diagnostic tools for applications in transplantation, oncology, autoimmunity, and infectious disease."

He added, "We are excited to now have a website where researchers can easily explore and purchase our inventory of over 250 Class I and Class II proteins in both unmodified and biotinylated forms and Pure Protein's peptide validation, screening and mapping services."

The website is a comprehensive source for HLA proteins, services and scientific resources that will be updated on a regular basis with new products, technical updates and company milestones. For more information visit https://www.hlaprotein.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma in 1999. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: http://www.pureproteinllc.com/.

Pure Protein is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/.

*LOGO link for media: https://www.Send2Press.com/300dpi/20-1125s2p-hla-protein-300dpi.jpg

Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website.

Related link: https://www.hlaprotein.com/

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Related link: https://www.zeteobiomed.com/

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va. /ScoopCloud/ -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology (San Antonio, TX), a company that has been exploring the health-related benefits of novel extracts of Nerium oleander for the past 25 years.

Avila Herbals began product development activities in the spring of 2020 and optimized several different proprietary extraction techniques. The company developed the formulation and the products and has scaled manufacturing in anticipation for a launch of several different products. Each product contains a unique extract from the Nerium oleander plant. Phoenix has filed several patent applications based on this work related to SARS-CoV-2 infection and the COVID-19 pandemic.

"We look forward to working with Phoenix Biotechnology. We are committed to developing and manufacturing several new oleander-based products with Phoenix," commented Dr. Richard Obiso, co-owner and CSO of Avila Herbals. "We are thrilled to be able to apply our research and manufacturing expertise to the development of these products."

The agreements support continued manufacturing so that the product can be made available in the United States and internationally. The agreements also cover the development and manufacture of a pharmaceutical, if clinical trials are approved by the US Food and Drug Administration (FDA); although the specific terms of the agreements were not disclosed.

Since Q2 CY2020, Avila Herbals and its partners have invested over $4.5 million dollars into the development and commercialization of these products in the New River Valley of Virginia. Avila has created more than 50 full-time jobs in just a few months to support the development and manufacturing of these products.

"Avila Herbals contributes to the economy of the New River Valley. The company's research and development of the potential health benefits of the extract of Nerium oleander is impressive, and we thank Avila and Phoenix for their commitment to the region and to the Commonwealth," said US Congressman Morgan Griffith.

According to Theresa Obiso, co-owner and CEO of Avila Herbals, "When we began our collaborations, we immediately scaled to meet this need; doing so here in Christiansburg allows us to leverage strong local relationships and build a world-class team."

"Avila Herbals' expansion is a significant win for our region's future and our growing economy," said Virginia Delegate Nick Rush. "Avila is a technology leader that exemplifies the New River Valley's entrepreneurial spirit," Delegate Rush continued. "I wish Avila Herbals much success as it moves forward to becoming one of SWVA's newest technology success stories."

About Avila Herbals

Avila Herbals has created a sustainable agriculture program in the New River Valley of Virginia that focuses on the production of the highest quality botanicals for use in nutraceuticals and botanical pharmaceuticals. The team uses supercritical carbon dioxide extraction as well as novel cryo-ethanol methods, and has launched several botanical preparations. Our passion is sustainable agriculture, organic techniques, and biodynamic farming practices. At Avila Herbals, we work hard to exceed regulatory standards, because we believe in sustainability and great quality. All of our products are manufactured in our GMP facilities.

About Phoenix Biotechnology

Phoenix Biotechnology, Inc. is a San Antonio, Texas-based biotechnology company that was incorporated in Texas in 2003 to develop promising agents from Nerium oleander with minimal or no side effects for targeted therapy in three areas: malignant tumor growth (an extract of Nerium oleander has been found to bind to discrete cellular targets in solid tumors in vitro and in vivo), neurological disorders (ischemic stroke, Alzheimer's disease, and Huntington's disease), and viral diseases. To date, Phoenix has identified potent antiviral activity against Ebola and Marburg viruses, cytomegalovirus, herpes simplex viruses, HIV and HTLV-1, and SARS-CoV-2.

For more information about Avila Herbals, please contact Avila Herbals at info@avilaherbals.com (preferred) or 1-540-808-2314.

On the web: https://avilaherbals.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/20-1028x2p-avila-herbals-300dpi.jpg

Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

Related link: https://avilaherbals.com/

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif. /ScoopCloud/ -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week. From close to 2900 posters, only roughly 10% were selected as outstanding posters.

Progenabiome will also present a second poster: "Detection and Mutational Analysis of SARS-CoV-2 From Patient Fecal Samples by Whole Genome Sequencing." The ACG 2020 Meeting will be held virtually on October 23-28, 2020, and both poster abstracts and presentations will be available online in the ACG 2020 ePoster Hall.

Last year, Dr. Sabine Hazan, CEO of Progenabiome, shared groundbreaking data on C.Diff discovered through genetic sequencing at the 2019 ACG Meeting. She is looking forward to sharing newly found data on C.Diff and also COVID-19 at this year's event.

Dr. Hazan also recently published new findings from a phase 2 trial on Eosinophilic Gastritis and Duodenitis in the New England Journal of Medicine (NEJM.) As a leading clinical trials investigator who has overseen more than 150 clinical trials, Dr. Hazan is dedicated to research and producing validated, verified, and reproduced data.

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, Progenabiome has 41 ongoing clinical trials related to immunity and disease, including five COVID-19 studies validating testing, prophylaxis, and at-home treatment protocols for the novel coronavirus.

For more information, visit:
https://progenabiome.com

https://clinicaltrials.gov

https://malibumicrobiomemeeting.com/

ACG ePoster Hall: https://eventscribe.com/2020/ACGPosters/

NEJM paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2012047

Media Contact:
Stephanie Davis
sdavis@progenabiome.com

*IMAGE Link for Media: https://www.Send2Press.com/300dpi/20-1026s2p-Progenabiome-data-300dpi.jpg

The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week.

Related link: https://progenabiome.com/

Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 - 21, 2020, where the Company will be previewing its soon to launch website https://www.hlaprotein.com/.

This new website will offer academic and commercial researchers access to individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Rico Buchli, Ph.D., Pure Protein's Director of Research commented, "For over 20 years, Pure Protein has provided technology and expertise to advance novel therapies and diagnostic tools for applications in transplantation, oncology, autoimmunity, and infectious disease."

He added, "We are excited to exhibit at ASHI 2020 and share the news about hlaprotein.com where we will soon be offering researchers 126 Class I and 154 Class II proteins in both unmodified and biotinylated forms, as well as access to Pure Protein's peptide validation, screening and mapping services."

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma in 1999. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: https://www.hlaprotein.com/.

Pure Protein is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: https://emergenttechnologies.com/.

Link to event information: https://www.ashi-hla.org/page/Meetings_Annual

Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 - 21, 2020.

Related link: https://www.hlaprotein.com/

Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery

STONY BROOK, N.Y. /ScoopCloud/ -- Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok's secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein targets:
1. The RNA-dependent RNA polymerase (which copies the virus inside the cell, thought to be the target of Gilead's Remdesivir, now in clinical trials)
2. The Protease (which chops up the virus proteins into the right pieces)
3. The spike protein (which is how the virus unlocks the door to enter the cell).

The Laufer Center is running their computationally-intense simulations to understand how proteins fold and how proteins bind to proteins - actions, mechanisms and binding affinities - to enable design of drugs for high-affinity binding to proteins. They apply state-of-the-art modeling, using physics-based methods to examine motions, forces and free energies within biological mechanisms. In a previous limited benchmarking program, the Laufer Center concluded that they achieved a 6x improvement in performance on Zeblok's platform compared to NSF's Blue Waters Cray GPU-based system. The structures of most COVID virus proteins are not yet known. Dr. Ken Dill's group is computing many of their structures using MELD x MD, while Dr. Dima Kozakov's group is computing structures of human-virus and virus-virus protein pairs.

"Companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure-activity relationship (QSAR), have now become an important part of the pharmaceutical industry. Drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations. Zeblok Computational platform levels the playing field for researchers that need accelerated infrastructure for R&D. We uniquely combine computing platforms, orchestration, multi-cloud and in silico software developers to deliver quality services for companies engaged in drug discovery," said Zeblok Computational CEO Mouli Narayanan.

Zeblok Computational is incubated at and supported by CEWIT, using its SMART cluster of 180 NVIDIA RTX 6000 GPUs. "Our dual-use homogenous SMART Cluster is one of the fastest GPU clusters in academia and supports dual-use of both deep learning and visualization in a variety of applications," said Dr. Arie Kaufman, the Chief Scientist and the SMART Cluster Director.

Mr. Narayanan further said, "We want to help data center operators at the grass roots level to offer AI and AI-Hyperconvergence capabilities to their customers, enabling them to participate in the AI ecosystem. Companies are confronted with so much data that they increasingly need AI enabled smart processes. Implementation of 5G is further driving the low latency requirement for AI-Inferencing at Edge data centers. Zeblok's orchestration engine seamlessly integrates multiple disparate resources into a complete AI model development environment all the way to the Edge, supported by its smart sourcing business model for surplus GPU capacity."

About Zeblok Computational

Zeblok Computational Inc. is an Artificial Intelligence Platform-as-a-Service, providing a single unified pre-configured environment, with familiar frameworks and languages as well as a growing library of carefully selected proven original AI algorithms, enabling data scientists to begin developing AI models in minutes, to scale effortlessly for model training and to deploy in a runtime environment, with AI expertise and high touch assistance in integrating AI solutions into enterprise business processes.

Zeblok's container-based engineering platform leverages familiar open source software, adding a sophisticated proprietary multi-class, multi-cloud orchestration engine that combines heterogeneous environments through abstraction and virtualization and includes built-in resource management, multi-tier workload distribution, both front-end and back-end services and scale-out resource availability in minutes. Zeblok's secure, smart sourced, Edge-connected accelerated infrastructure comprises a multi-cloud of over 7,000 GPUs, enabled by partnerships with the CEWIT and others.

For more information: https://www.computational.zeblok.com/

About The Laufer Center

The Louis and Beatrice Laufer Center, established in 2008 to advance biology and medicine through discoveries in physics, mathematics and computational science, is a hub for Physical and Quantitative Biology research at Stony Brook University. Laufer Center researchers come from several Stony Brook departments and Cold Spring Harbor Laboratory.

For more information: https://laufer-covid.org/ and http://laufercenter.stonybrook.edu/

About CEWIT

New York's Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University is a next-generation research and educational facility with a mission to conduct interdisciplinary applied research in emerging and critical technologies, address the skilled technology worker shortage and to foster new enterprise development in wireless and IT communications, infrastructure, networking, and software. When CEWIT upgraded its accelerated infrastructure to a smart cluster of over 180 NVIDIA RTX 6000 GPUs in 2019, they realized they needed to orchestrate the various resources to achieve seamless distribution of compute power throughout the university, which led to its partnership with Zeblok.

For more information: https://www.cewit.org/

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0720-zeblok-logo-300dpi.jpg

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok's secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

Related link: https://www.computational.zeblok.com/

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif. /ScoopCloud/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

During the Phase 1b trial, ROKiT Pharma's goal will be to determine the safety and tolerability of the drug in humans, as well as understand the pharmacokinetic and pharmacodynamic properties. If ROK-001 gains IND approval, ROKiT Pharma would like to open its first clinical trial during the summer of 2020. Discussions are currently underway with two prominent hospitals for this trial.

"The University of Sydney found the naturally occurring compounds on Kangaroo Island, we then completed our multiyear process of developing the synthetic processes and patenting the compound and related analogs," said Dean Becker, chairman and CEO of ROKiT Pharma and globally recognized leader in IP strategy. "Our plan is to produce large quantities of the drug - enough for universal need - so that we can really help people combat this disease through more natural sources. Unleashing nature is our goal - we want to provide these potentially life prolonging drugs, in oral pill form, at a projected cost under $1,500 per month."

The patented chemical platform of ROKiT Pharma's key drugs have unprecedented in vitro and in vivo efficacy on 29 major types of cancer (intriguingly, showing activity on p53, AP-1, and NF-kB). Importantly, selective toxicity of ROK-001 on cancer cells rather than non-neoplastic (healthy) cell lines account for its' high therapeutic index, while safety profile evaluations confirm that the compound exerts no genotoxicity nor cardiotoxicity.

Given these results, ROKiT Pharma narrowed its focus for its' first clinical trial to some of the worst cancers that have no current cure - pancreatic and brain (specifically Glioblastoma Multiforme and patients who have had metastases to the brain from other organs).

"Once ROKiT Pharma is able to get FDA approval in one adult cancer type, we plan to divert our focus to childhood cancers," said John Paul DeJoria, ROKiT co-founder and founder of Paul Mitchell Systems and Patron Tequila. "As ROKiT continues to grow globally, we are continuing to add companies that really fulfill our humanitarian goals. Success unshared is failure."

The naturally derived anticancer compounds used to create ROK-001 were discovered through the propolis of Ligurian honey bees only found on Kangaroo Island, which lies off the mainland of South Australia. Propolis is a mixture of beeswax, saps and resins.

In animal studies, ROK-001 demonstrated great efficacy in a multitude of cancer models including pancreatic, melanoma, kidney, bladder, and breast, some in as early as seven days post-oral treatment. Aside from efficacy information, ROK-001 was specifically formulated for oral delivery that not only demonstrated nice biodistribution, but it also revealed that ROK-001 can cross the blood-brain barrier in mice. This discovery led to the decision to target brain cancers.

ROKiT Pharma hopes to fast track this relatively low-toxicity drug for patients with the most deadly cancers. With any proven efficacy in the Phase 1b clinical trial, the FDA may allow an immediate Phase 2 trial to start with an expanded cohort and patient population.

Upon IND approval of ROK-001, the company plans to make the drug available for "Compassionate Use" as is now allowed under the "Right To Try Act" that President Trump signed in 2018.

ROKiT Pharma is presently designing and planning a manufacturing facility (or contract manufacturing facility) in Puerto Rico to act as an established hub for global distribution.

"As the ROKiT brand's awareness continues to grow through our global sports sponsorships - ROKiT Williams Racing Formula 1, ROKiT Venturi Racing Formula E, the Houston Rockets, the Las Vegas Raiders - we are elated to be aggressively entering the pharmaceutical marketplace," said Jonathan Kendrick, co-founder of ROKiT.

The company is optimistic that ROK-001 will move straight into at least one Phase 2 trial and is currently adding philanthropic investors to its capital base.

If there is interest in learning more about ROKiT Pharma or for philanthropic inquiries, please contact info@rokitpharma.com for further information.

About ROKiT Pharma

ROKiT Pharma is a late stage preclinical pharma company focusing its research efforts on cancer. The corporation has an extensive global intellectual property portfolio. Research was developed at and in conjunction with the University of Sydney.

Additional information (*new site under construction Q2/2020): https://www.rokitpharma.com/

Media Contact:
Kristyn Clark
Senior PR Manager
ROKiT Pharma
Tel: (805) 231-1572
kristyn.clark@rokit.com

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0402s2p-rokit-pharma-300dpi.png

ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

Related link: https://www.rokitpharma.com/

Lyme Disease Biobank Expands Into San Diego

SAN DIEGO, Calif. /ScoopCloud/ -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

Congressman Scott Peters and Councilmember Chris Cate are scheduled to speak at the ribbon-cutting ceremony for the new collection site, and Council President Pro Tem Barbara Bry, Senator Toni Atkins, and Assemblymember Todd Gloria will send representatives to issue commendations to support this event.

"Lyme disease is a growing problem in the County of San Diego, because many of our residents travel to or relocate from other more highly endemic areas and it is also possible to be infected locally," said Sharon Wampler, PhD, who was instrumental in bringing Bay Area Lyme Foundation's Lyme Disease Biobank to San Diego. "As a world-class hubfor research and innovation, we can be part of the solution. This biobank is an important resource which will help researchers answer many current scientific questions about tick-borne diseases."

Much research into tick-borne infections is needed, as current diagnostics are inaccurate for more than half of early stage Lyme disease cases, treatments do not work for everyone and late stage Lyme disease can become nearly impossible to cure. In fact, a recent study based on the samples collected by the Lyme Disease Biobank and published in the Journal of Clinical Microbiology, a journal of the American Society for Microbiology, found that the Centers for Disease Control's standard two-tier testing algorithm for Lyme disease failed to accurately diagnose 71% of blood samples from individuals in endemic areas presenting with a Lyme rash, also known as an erythema migrans, greater than 5 cm. In striving to investigate better diagnostics and treatments for tick-borne diseases, researchers require verified blood, urine and tissue samples to use in their studies.

Currently, there are 50 research projects that rely on Lyme Disease Biobank samples. The San Diego collection center will be in partnership with Osteopathic Medical Associates of San Diego (OMASD).

"As Lyme disease grows in prevalance, we are seeing more people looking to make a difference for current and future patients, and our biobank offers a valuable way for the public to support researchers who are working to find solutions," said Liz Horn, PhD, principal investigator, Lyme Disease Biobank. "We are honored to be able to give people from San Diego the opportunity to contribute to this important initiative."

The Lyme Disease Biobank in San Diego will collect from people who have ongoing symptoms of Lyme disease. Importantly, because bacterial strains of tick-borne diseases have been shown to vary from region to region, a biobank in San Diego will allow researchers to explore potential new diagnostics against the range of bacterial strains prevalent in people with Lyme disease in San Diego, along with those from other parts of the country.

San Diego residents are also invited to register for the Biobank's tissue collection program. This program allows for a greater understanding of the ability of Lyme bacteria to invade tissues and organs. The Lyme Disease Biobank is the only national entity working to accelerate research by collecting surgical and post-mortem tissue samples from individuals with persistent Lyme disease and other tick-borne infections.

Also in support of Lyme disease research such as this, community members will come together tonight, Friday, March 6 for Ride Out Lyme California at SoulCycle in La Jolla.

About Lyme Disease Biobank

The Lyme Disease Biobank (LDB), a program of the Bay Area Lyme Foundation, is a non-profit organization working to accelerate research of Lyme disease and other tick-borne infections. With a collection of biological samples from more than 900 participants, including serum, blood, urine and tissue, LDB provides much-needed samples to researchers working to better understand tick-borne diseases and develop improved tests and therapeutics. Blood and urine samples are collected from the Northeast, Upper Midwest and West Coast areas of the U.S., and tissue samples are collected throughout the country.

Healthcare providers looking to get involved, and patients interested in donating blood, urine or tissue samples can learn more here - https://www.bayarealyme.org/our-research/biobank/patient-information/

Researchers interested in obtaining samples should visit https://www.bayarealyme.org/ or contact info@lymebiobank.org.

About Lyme Disease

The most common vector-borne infectious disease in the country, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and unreliable diagnostic tests. There are more than 400,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, more than one million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.

About Bay Area Lyme Foundation

Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is a leading public not-for-profit sponsor of innovative Lyme disease research in the U.S. A 501c3 non-profit organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM Fund covers overhead costs and allows for 100% of all donor contributions to Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit https://www.bayarealyme.org/ or call us at 650-530-2439.

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

Related link: https://www.bayarealyme.org/

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

ASH abstracts are now available at https://www.hematology.org/.

Oral Presentation:

Title: First-in-Human Trial of BCMA-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction
Session: 721. Abstract Number: 38
Saturday, December 7, 2019: 7:45 a.m.
Valencia BC (W415BC), Level 4 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162353

Poster Presentation:

Title: First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma
Session: 626. Abstract Number: 2881
Sunday, December 8, 2019, 6 p.m. to 8 p.m.
Hall B, Level 2 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162340

About BCMA-CD19 cCAR therapy

BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA and CD19. The diseases treated by BCMA-CD19 cCAR could include autoimmune disorders, and organ rejection. BCMA is expressed in plasma cells, while CD19 is related to B-cells. BCMA-CD19 cCAR is designed to completely remove antibody-producing "roots", plasma cells and B cells, and then re-set the immune system for treating antibody-mediated autoimmune disorders or organ rejections.

BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

About CD4-specific CAR (CD4 CAR) therapy

CD4-specific CAR with a safety switch is designed to treat peripheral T cell lymphoma as CD4 is uniformly expressed on most mature T cell lymphoma, and transient depletion of CD4 is expected. The diseases treated by CD4 CAR could include peripheral T-cell lymphoma (NOS), Sezary syndrome/cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T cell lymphoma, T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia/lymphoma and T-cell large granular lymphocytic leukemia. Most of these diseases are difficult to treat, with dismal prognoses. An IND has been approved for iCell Gene Therapeutics to initiate a multi-site clinical trial at Stony Brook University Hospital and University of Louisville.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Clinical studies on our CARvac, T-cell targeted CARs, Compound CARs, Non-gene edited universal CARs and C-TPS1 (depletion of TREG, blockage of PD-L1 pathways and stimulation of tumor infiltrating lymphocytes) for solid tumors are ongoing in the US and in China.

For more information, please visit http://icellgene.com/

Contact:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

Related link: http://icellgene.com/

Hans van der Sluijs Joins BioTork as Chief Development Officer

GAINESVILLE, Fla. /ScoopCloud/ -- BioTork, the leading evolution biotechnology company, today announced that biotech executive Hans van der Sluijs has joined the company as Chief Development Officer. Hans brings over 20 years of international business leadership experience, with a focus on business development, management, and building strategic alliances/partnerships. Hans will be responsible for commercializing BioTork's technology globally.

"I'm very excited to join BioTork at this stage of their development, the company possesses a unique technology and has made great strides over the past years," said Hans. "Nature continuously develops and BioTork leverages that with their adaptive evolution technology; the opportunities are endless."

"We are looking ahead to 2020, and are happy to have the opportunity to strengthen our management team with the additions of industry veterans such as Hans van der Sluijs and Mark DeAndrea earlier this month," said Eudes de Crecy, CEO and Founder of BioTork. "We believe we have the right leadership in place to guide BioTork forward and gain the necessary market penetration to become an industry standard."

Renewable fuels and bio-based alternatives are becoming increasingly more important as the world shifts from oil to bio-based products. BioTork harnesses its proprietary adaptive evolution technology to create optimum non-GMO cellular factories for the conversion of agricultural by-products, co-products and feedstock into desirable commodities or specialties.

This better positions clients to leverage their production of sustainable biomaterials, thus dramatically improving efficiency while also reducing their carbon footprint.

BioTork's diverse approach can be used to improve upon any organism, whether it be GMO, non-GMO, and organic.

Most recently, as Vice President Business & Strategy - Americas for DSM Bio-based Products & Services, Hans built the North American team, delivered on the strategic objectives, shaped new ways for growing the emerging business including launching new biotechnology into the ethanol market, and significantly grew revenue through strategic partnerships and license agreements.

Previously, Hans served as Joint Venture Director for POET-DSM Advanced Biofuels. He played a leadership role in establishing and managing the partnership to build and operate the world's first commercial scale cellulosic ethanol plant. Hans's international leadership experience also includes strategic projects (M&A) and finance management, for DSM's antibiotic division and an international food company.

About BioTork:

BioTork is the leading evolution biotechnology company that focusses on the development and improvement of organisms. The company develops and improves scalable, highly efficient, and robust microorganisms and adapts them to their related industrial processing conditions. BioTork's technology has numerous applications in industries like agriculture, biofuels, biomaterials, chemicals, consumer products, pharmaceutical, pulp and paper, food, and feed.

Learn more at: https://biotork.com/

*PHOTO link for media: https://www.Send2Press.com/300dpi/19-1030s2p-Hans-van-der-Sluijs-300dpi.jpg

BioTork, the leading evolution biotechnology company, today announced that biotech executive Hans van der Sluijs has joined the company as Chief Development Officer. Hans brings over 20 years of international business leadership experience, with a focus on business development, management, and building strategic alliances/partnerships.

Related link: https://biotork.com/

Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Josh Makower, general partner at VC firm New Enterprise Associates, will keynote on the first day of the conference. Makower is cofounder of the Stanford Byers Biodesign Center and also founder and executive chairman of ExploraMed, a medical device incubator that has created eight companies over the past 20 years.

Robert Knight, professor of psychology and neuroscience and director emeritus of the Helen Wills Neuroscience Institute at UC Berkeley, will deliver the keynote on the second day of the event. Knight is the recipient of the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health for distinguished contributions to neurological research. He is also the chief science advisor of Neurofocus Inc., the consumer neurotech spinoff company acquired by market research firm Nielsen.

The agenda for this year's event includes panel discussions on a number of topics, including sessions devoted to clinical trials, securing funding, the new competitive landscape in neuromodulation, closed-loop stimulation, and neurorehabilitation. New this year is an editorial roundtable featuring Neurotech Reports editors James Cavuoto, Jennifer French, Jeremy Koff, and Margot Puerta, who will each offer their perspectives on issues confronting the industry.

Among the companies presenting this year are Saluda Medical, Nia Therapeutics, Neuroelectrics, Humm, Evoke Neuroscience, Neural Dynamics Technologies, Spark Biomedical, Thermaquil, Humm, Neuraura, CareWear, Rune Labs, Neural Signals, and BIOS.

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Maynard Cooper and Integer are Silver Sponsors, and RBrooks Group, Senso Medical, and the Cleveland FES Center are Bronze Sponsors.

"We're excited about the lineup of speakers at this year's event," said James Cavuoto, editor and publisher at Neurotech Reports. "As in the past, attendees will have many opportunities to interact with potential partners and colleagues."

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/leadersforum.html.

Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Related link: http://www.neurotechreports.com/